Galderma announces US FDA approval of its ‘Restylane Lyft with Lidocaine’
Published November 7, 2025 Dermatology business Galderma has announced that the US’s Food and Drug Administration has approved its ‘Restylane Lyft with Lidocaine’ product, designed for chin augmentation and to improve the chin profile in patients over the age of 21 with mild-to-moderate chin retrusion. Galderma offers a range of HA injectables – Reuters “This…


